Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome.

Ellegård L, Bosaeus I, Nordgren S, Bengtsson BA

Annals of surgery1 Jan 1997Cited by 89 (Europe PMC)

PMID8998124DOI10.1097/00000658-199701000-00010PepBankPUB-08998124

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In short bowel syndrome patients, low-dose rhGH doubled serum IGF-1.
In plain wordsIn short bowel syndrome patients, low-dose rhGH doubled blood IGF-1.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum IGF-1
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Low-dose rhGH doubled serum levels of insulin-like growth factor-1 (IGF-1) and increased body weight, lean body mass, and total body potassium by 5% (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812401
02HumanRandomized controlled trialEfficacy outcome
In short bowel syndrome patients, low-dose rhGH increased body weight by 5% (p < 0.05).
In plain wordsIn short bowel syndrome patients, low-dose rhGH increased body weight by 5%.
Peptide
HGH (somatotropin)
Outcome
IncreaseBody weight
Study
n = 10
Outcome group
Body weight · Metabolic and weight
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Measurements
Body weight increase
5%
low-dose rhGH
Source sentences
Summary
Low-dose rhGH doubled serum levels of insulin-like growth factor-1 (IGF-1) and increased body weight, lean body mass, and total body potassium by 5% (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812402
03HumanRandomized controlled trialEfficacy outcome
In short bowel syndrome patients, low-dose rhGH increased lean body mass by 5% (p < 0.05).
In plain wordsIn short bowel syndrome patients, low-dose rhGH increased lean body mass by 5%.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass
Study
n = 10
Outcome group
Body composition · Metabolic and weight
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Measurements
Lean body mass increase
5%
low-dose rhGH
Source sentences
Summary
Low-dose rhGH doubled serum levels of insulin-like growth factor-1 (IGF-1) and increased body weight, lean body mass, and total body potassium by 5% (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812403
04HumanRandomized controlled trialEfficacy outcome
In short bowel syndrome patients, low-dose rhGH increased total body potassium by 5% (p < 0.05).
In plain wordsIn short bowel syndrome patients, low-dose rhGH increased total body potassium by 5%.
Peptide
HGH (somatotropin)
Outcome
IncreaseTotal body potassium
Study
n = 10
Outcome group
Body composition · Metabolic and weight
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Measurements
Total body potassium increase
5%
low-dose rhGH
Source sentences
Summary
Low-dose rhGH doubled serum levels of insulin-like growth factor-1 (IGF-1) and increased body weight, lean body mass, and total body potassium by 5% (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812404
05HumanRandomized controlled trialEfficacy outcome
In short bowel syndrome patients, fat-free mass increased by 6% during rhGH treatment (p = 0.008).
In plain wordsIn short bowel syndrome patients, fat-free mass increased by 6% during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFat-free mass
Study
n = 10
Outcome group
Body composition · Metabolic and weight
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Measurements
Fat-free mass increase
6%
low-dose rhGH
Source sentences
Summary
Fat-free mass and total body water increased by 6% (p = 0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812405
06HumanRandomized controlled trialEfficacy outcome
In short bowel syndrome patients, total body water increased by 6% during rhGH treatment (p = 0.008).
In plain wordsIn short bowel syndrome patients, total body water increased by 6% during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseTotal body water
Study
n = 10
Outcome group
Body composition · Metabolic and weight
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Measurements
Total body water increase
6%
low-dose rhGH
Source sentences
Summary
Fat-free mass and total body water increased by 6% (p = 0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812406
07HumanRandomized controlled trialEfficacy outcome
In short bowel syndrome patients, rhGH did not significantly change water absorptive capacity.
In plain wordsIn short bowel syndrome patients, rhGH did not significantly change water absorption.
Peptide
HGH (somatotropin)
Outcome
No significant changeWater absorption
Study
n = 10
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
No significant changes in absorptive capacity of water, energy, or protein were detected.
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812408
08HumanNon-randomized trialEfficacy outcome
In short bowel syndrome patients, rhGH did not significantly change energy absorptive capacity.
In plain wordsIn short bowel syndrome patients, rhGH did not significantly change energy absorption.
Peptide
HGH (somatotropin)
Outcome
No significant changeEnergy absorption
Study
n = 10
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
No significant changes in absorptive capacity of water, energy, or protein were detected.
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812409
09HumanNon-randomized trialEfficacy outcome
In short bowel syndrome patients, rhGH did not significantly change protein absorptive capacity.
In plain wordsIn short bowel syndrome patients, rhGH did not significantly change protein absorption.
Peptide
HGH (somatotropin)
Outcome
No significant changeProtein absorption
Study
n = 10
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
No significant changes in absorptive capacity of water, energy, or protein were detected.
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812410
10HumanObservational studyMechanism
In short bowel syndrome patients receiving rhGH, IGF-1 increases correlated with fat-free mass increases (r = 0.77, p < 0.02).
In plain wordsIn short bowel syndrome patients receiving rhGH, IGF-1 increases correlated with increases in fat-free mass.
Peptide
HGH (somatotropin)
Outcome
Not applicableIGF-1 and fat-free mass correlation
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.024 mg/kg-1 per day-1 (0.5 international units/kg-1 per week-1) · subcutaneous · 8 weeksAs given in this study (human).
Measurements
Correlation coefficient (IGF-1 increase vs fat-free mass increase)
0.77 r
patients receiving rhGH
Source sentences
Summary
Increases in IGF-1 levels correlated with increases in fat-free mass (r = 0.77, p < 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
The authors investigate the effects of low dose recombinant human growth hormone (rhGH) on body composition and absorptive capacity in patients with short bowel syndrome from Crohn's disease.
Summary · context
Ten patients were treated with daily subcutaneous doses of rhGH/placebo (0.5 international units/kg-1 per week-1 = 0.024 mg/kg-1 per day-1) for 8 weeks in a randomized, double-blind, placebo-controlled crossover clinical trial with a minimum of 12 weeks wash-out.
Report a problemFND-0899812407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.